Home

Insights

Unichem Laboratories Ltd P/E Ratio

Unichem Laboratories Ltd P/E Ratio

download
stocks purchased

₹ 0.1 Cr

Volume transacted

stocks purchased

1.4 K

stocks traded

Image

Unichem Laboratories Ltd

NSE: UNICHEMLAB

PE

0

Last updated : 20 Jun 06:49 AM

Key Highlights

    The P/E Ratio of Unichem Laboratories Ltd is 0 as of 20 Jun 06:49 AM .a1#The P/E Ratio of Unichem Laboratories Ltd changed from 63.4 on March 2019 to 0 on March 2023 . This represents a CAGR of -100.00% over 3 years. a1#The Latest Trading Price of Unichem Laboratories Ltd is ₹ 531.05 as of 20 Jun 12:13 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 11.3. The PE Ratio of Finance industry is 31.6. The PE Ratio of IT - Software industry is 28.9. The PE Ratio of Pharmaceuticals industry is 101.4. The PE Ratio of Retail industry is 142.7. The PE Ratio of Textiles industry is 7.2. In 2024a1#The Market Cap of Unichem Laboratories Ltd changed from ₹ 1369 crore on March 2019 to ₹ 2035 crore on March 2023 . This represents a CAGR of 8.24% over 5 years. a1#The Revenue of Unichem Laboratories Ltd changed from ₹ 317.46 crore to ₹ 437.85 crore over 8 quarters. This represents a CAGR of 17.44% a1#The EBITDA of Unichem Laboratories Ltd changed from ₹ 6.88 crore to ₹ -94.12 crore over 8 quarters. This represents a CAGR of NaN% a1#The Net Profit of Unichem Laboratories Ltd changed from ₹ -23.37 crore to ₹ -129 crore over 8 quarters. This represents a CAGR of 135.23% a1#The Dividend Payout of Unichem Laboratories Ltd changed from 320 % on March 2019 to -9.4 % on March 2023 . This represents a CAGR of NaN% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '190
Mar '200
Mar '2163.4
Mar '2255.4
Mar '230

Fundamental Metrics

Market Cap

3,795 Cr

EPS

0.0

P/E Ratio (TTM) *

0.0

P/B Ratio (TTM) *

1.6

Day’s High

541.0

Day’s Low

528.3

DTE *

0.1

ROE *

-0.9

52 Week High

616.0

52 Week Low

365.35

ROCE *

0.7

* All values are consolidated

Last Updated time: 20 Jun 06:49 AM

* All values are consolidated

Last Updated time: 20 Jun 06:49 AM

Image

Unichem Laboratories Ltd

NSE: UNICHEMLAB

PRICE

531.05

-8.10 (-1.50%)

stock direction

Last updated : 20 Jun 12:13

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Unichem Laboratories Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value

Market Value

3,796

Asset Value

1,600

1.4 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Company NamePEMarket Cap (INR Cr.)
Sun Pharmaceuticals Industries Ltd36360,896
Cipla Ltd29125,905
Divis Laboratories Ltd74118,864
Zydus Lifesciences Ltd28108,024
Dr Reddys Laboratories Ltd1799,341
Unichem Laboratories Ltd03,795

Key Valuation Metric

Earnings

-70 Cr

0.0 X

PE Ratio

Market Cap

₹3795Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

-70 Cr

0.0 X

PE Ratio

Market Cap

₹3795Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '191370
Mar '201066
Mar '212178
Mar '221833
Mar '232035

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22317
Sep '22338
Dec '22319
Mar '23407
Jun '23432
Sep '23421
Dec '23514
Mar '24438

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '227
Sep '22-14
Dec '22-26
Mar '23-12
Jun '2337
Sep '2314
Dec '23117
Mar '24-94

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '22-23
Sep '22-71
Dec '22-64
Mar '23-44
Jun '23-1
Sep '23-24
Dec '2384
Mar '24-129

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '19320
Mar '20-50
Mar '2152
Mar '22-51
Mar '23-9

* All values are a in %

About Unichem Laboratories Ltd

About Unichem Laboratories Ltd

    Unichem Laboratories Ltd is an India-based pharmaceutical company, which manufactures active pharmaceutical ingredients. The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division. The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh. The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The Baddi plant was approved by UK MHRA and MCC (South Africa). The company received ISO 9001:2000 for all their plants and corporate office. Also, they received ISO 14001:2004 certificates for their formulation plants located at Goa, Ghaziabad and Baddi and the corporate office at Mumbai. Unichem Laboratories Ltd was incorporated in the year 1962. The company was formed by Amrut V Mody to take over a proprietary business set up in 1944 in Mumbai. They made a foreign collaboration with UCB for bulk drugs and set up first formulation plant at Jogeshwari. In the year 1963, they made a tie up with Uni Sankyo Co-Marketing formulations. In the year 1968, the company set up formulations plant Ghaziabad and in the year 1976, they set up a fine chemicals unit at Roha. In the year 1984, the company entered an agreement with Upjohn and set up Unisearch Ltd. Also, they entered into the anti-biotic segment and launched Ampoxin, an Ampicillin & Claxacillin combination during the year. In the year 1987, the company entered the Animal Health Care business. In the year 1996, Unichem Exports Ltd and Unisearch Ltd were merged with the Unichem Laboratories Ltd. In the year 1997, the company set up new corporate office at Mumbai and in May 1997, the company's state-of-the-art formulation plant at Bardez, Goa was successfully commissioned and commercial production was started. In the year 1998, their plant at Baddi, Himachal Pradesh for Antibiotics was completed. In the year 1999, the company set up modern multipurpose bulk drug plant at Roha. In April 1, 1999, the company launched their new Division, namely Foreva catering to Women's Healthcare. In February 2000, they set up their Molecular Generic Division, which launched 23 new products in the two months of the financial year 1999-2000. Also, the company purchased two brands, namely Emcredil and Candizole-T for a total cost of Rs 132 lakh during the financial year 1999-2000. In the year 2001, the company set up new R&D centre at Mumbai. Also, they set up new Biosciences R&D centre at Bangalore in association with Indian Institute of Sciences for research work in Bio-technology. In April 2002, the company established a joint venture company with Bioglan Generics Ltd, namely Niche Generics Ltd with 60% stake. During the year 2002-03, they divested their animal healthcare division. They upgraded the Ghaziabad plant with an investment of Rs 250 million. Also, they started a representative office in Kiev, Ukraine. In March 2003, Unichem SA Pty Ltd became a subsidiary of the company. In the year 2004, they restructured Unisearch and launched Unisearch CD Division. In the year 2005, the company set up a New Pharma Technology Development Center at Goa. Also, they acquired API manufacturing unit at Pithampur. Further, the company set up their second formulations plant at Baddi and production commenced in April 2005. In May 2005 the company disposed off their old factory at Jogeshwari (West) Mumbai for a consideration of Rs 136.50 million. During the year 2005-06, the company set up a wholly owned subsidiary Unichem Pharmaceuticals (USA) Inc, in USA. During the year 2006-07, the company started Unichem Specialities Division and launched 11 new products in various therapeutic segments. In December 20006, they acquired the remaining 60% stake in Niche Generics Ltd of UK and thus Niche Generics Ltd became a wholly owned subsidiary company. During the year 2007-08, the company launched Unikare Division, which caters to Dermatology and Allied therapies. They also launched 27 new products in various therapeutic segments during the year. The company has initiated projects including setting up of a Formulation Plant at Sikkim and the expansion of their existing formulation facility at Baddi in Himachal Pradesh. The Company launched new division focusing on nephrology in cardiology segment during 2009. It commissioned new formulation plant at Sikkim, which is a solid oral dosage form facility, commissioned a new unit at Baddi for manufacturing all dosage forms of Cephalosporin and launched 19 new products during 2010. In 2011, the Company launched 22 new brands in various in various therapeutic segments. 4 new brands were launched in Cardiac Care, 3 in Dermatology and 2 in Neuropsychiatry amongst others. During year 2011-12, a Scheme of Arrangement between AVM Capital Services Private Limited, Chevy Capital Services Private Limited, PM Capital Services Private Limited, Pranit Trading Private Limited and Viramrut Trading Private Limited and Unichem Laboratories Limited was approved by the Hon'ble High Court vide Order dated July 12, 2012 and as a result, the Scheme became effective on August 6, 2012. The Company incorporated a new subsidiary in Ireland taking the total number of subsidiaries to 5 in March, 2012. In 2013, the Company completed dosage formulations facility at SEZ Pithampur and made agreement to sell the same to Mylan Laboratories Limited. During the year 2015, Synchron Research Private Limited became an Associate of Company. The Company, in December 2017, transferred its business of manufacture, sale, marketing and distribution of domestic formulations in India and Nepal, and the manufacturing facility at Sikkim together with all assets and liabilities through slump sale on a going concern basis, to Torrent Pharmaceuticals Limited on mutually agreed terms and conditions. The Company incorporated a Wholly Owned Subsidiary in China on June 27, 2019 under the name 'Younikaimo Pharmaceutical (Shanghai) Private Limited' in 2020.

Unichem Laboratories Ltd News Hub

News

Unichem Lab net loss widens to Rs 129 cr in Q4

Revenue from operations rose 7.36% year on year (YoY) to Rs 431.70 crore in the quarter en...

Read more

22 May 202415:30

News

Unichem Laboratories schedules board meeting

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 22 Ma...

Read more

10 May 202411:53

News

Unichem Lab hits life high on turnaround Q4 numbers

Revenue from operations jumped 43.6% year on year (YoY) to Rs 434.38 crore in the quarter ...

Read more

05 Feb 202415:24

News

Unichem Laboratories to discuss results

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 5 Feb...

Read more

16 Jan 202411:15

News

Unichem Laboratories to declare Quarterly Result

Unichem Laboratories will hold a meeting of the Board of Directors of the Company on 1 Nov...

Read more

19 Oct 202312:22

News

Unichem Labs gets USFDA nod for Prasugrel tablets

The approved abbreviated new drug application (ANDA) is a generic version of Effient (Pras...

Read more

30 Aug 202312:57

Product Composition by Percentage (Revenue)

FAQs for PE of Unichem Laboratories Ltd

What is Unichem Laboratories Ltd current share price?

The current market price of Unichem Laboratories Ltd as of June 20, 2024 is ₹531.05.

What is Unichem Laboratories Ltd's market cap?

Unichem Laboratories Ltd's market capitalisation stood at ₹3,795 Cr as of June 20, 2024

What are Unichem Laboratories Ltd's total net assets?

According to Unichem Laboratories Ltd's most recent financial filings, the company's net assets total ₹1600.4 Cr.

Is Unichem Laboratories Ltd making a profit or loss?

Unichem Laboratories Ltd's net Profit as of June 20, 2024 is close to ₹-70 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199